Nature Medicine · 2024 Stem Cell Therapy
41% Relapse rate reduction
Autologous Stem Cell Infusion in Relapsing-Remitting Multiple Sclerosis: Phase II Safety and Efficacy Data
The study
Autologous Stem Cell Infusion in Relapsing-Remitting Multiple Sclerosis: Phase II Safety and Efficacy Data. Nature Medicine. 2024
Published research is summarised here for general information. It is not a description of, or a promise about, any individual treatment.